Quick answer: there is no established KPV dosage for people. FDA’s July 2026 review found no clinical studies and no human exposure data for KPV by any route, so no human dose has ever been tested.[1] The only doses on record come from mice, mostly KPV dissolved in drinking water at 100 micromoles per liter (about 34 mg per liter).[2][6]
This guide lists what the animal studies actually used, why those amounts cannot be turned into a daily human dose, and what FDA said in 2026. For the background on the peptide itself, see our KPV profile; for safety, see KPV side effects; and for the wider field, the healing and gut peptides hub.
Is there a human KPV dose?
No. KPV is a three-amino-acid fragment (lysine, proline, valine) of the hormone alpha-MSH. It is not part of any FDA-approved drug, and it has no official drug standard.[1] In its 2026 review, FDA reported that:
- Neither the nominator nor FDA found any clinical study of KPV in humans.[1]
- There were no human or animal pharmacokinetic studies, meaning nobody has measured how KPV is absorbed, spread through the body and cleared.[1]
- There were no animal toxicity studies to show which amounts might be harmful.[1]
Without those three pieces, there is no scientific basis for a starting dose, a daily dose or a maximum dose in people. A ClinicalTrials.gov search we ran in October 2026 also returned no registered trials of KPV.
KPV dosage chart: what the animal studies used
The table below covers the published colitis studies that state a dose. All were in mice, and all gave KPV by mouth.
| Study | How KPV was given | Amount | Length |
|---|---|---|---|
| Emory University, 2008 | Dissolved in drinking water | 100 micromoles per liter | During chemically induced colitis |
| Georgia State University, 2016 | Dissolved in drinking water | 100 micromoles per liter | Two 7-day colitis cycles; 13 weeks in a genetic tumor model |
| Emory University, 2010 | Nanoparticles in a gel, by mouth | Not stated in the abstract; about 12,000 times less than plain KPV for a similar effect | During colitis |
| Georgia State University, 2017 | Targeted nanoparticles in a gel, by mouth | 16 micrograms per kilogram per day | During colitis |
Sources: Emory 2008,[2] Georgia State 2016,[6] Emory 2010[4] and Georgia State 2017.[5]
A German team at the University of Münster also treated mice with colitis using KPV and reported faster recovery, but the published summary does not state the dose.[3]
How those doses were chosen
The Emory team picked 100 micromoles per liter because earlier studies had used that level of alpha-MSH to treat colitis in mice. They said they chose a high concentration to improve the odds that enough KPV would reach the colon.[2] In other words, the dose was a practical starting point for a lab experiment, not the result of a dose-finding study.
Using the molecular weight FDA lists for KPV (342.43 grams per mole),[1] 100 micromoles per liter equals about 34 mg of KPV in each liter of the animals’ water, by our calculation. The mice drank as much as they wanted, so the exact amount each one took in was not measured.
In lab dishes, much smaller amounts were active. Nanomolar levels of KPV (billionths of a mole per liter) dampened two major inflammation pathways, NF-kB and MAP kinase, in human gut and immune cells.[2]
Why mouse doses don’t convert to people
People often try to scale an animal dose up by body weight. For KPV, that approach has several problems:
- No absorption data. No study has measured how much swallowed KPV reaches the bloodstream or the lining of the gut in people.[1]
- The transporter matters. KPV gets into gut cells through a transporter called PepT1. In mice whose PepT1 gene was switched off, KPV lost its protective effect in a colitis-linked tumor model.[6] How active this transporter is in a given person’s colon is not known in advance.
- Delivery changes everything. As the next section shows, packaging KPV differently changed the effective amount by thousands of times.
- Mice had induced disease. The colitis was caused by chemicals in otherwise healthy animals, which is not the same as long-term Crohn’s disease or ulcerative colitis.
Delivery changes the dose
Much of the KPV research since 2008 has been about getting the peptide to the colon intact:
- 2010: loading KPV into tiny particles wrapped in a gel let researchers use a concentration about 12,000 times lower than free KPV in solution, with similar benefit in mouse colitis.[4]
- 2017: particles coated to stick to inflamed colon cells worked better than uncoated particles, at 16 micrograms per kilogram per day.[5]
- 2026: a chemically protected version called proKPV built up in the inflamed colon about 3.8 times more than free KPV and worked even at a 20-fold lower dose.[7]
These results suggest that plain KPV, as sold in capsules or vials, may behave very differently from the engineered forms that produced the most striking mouse results. Our KPV capsules guide covers the oral question in more depth.
Injected or topical KPV
No study has given KPV by injection for gut inflammation, so there is no injected dose to report.[1]
For skin, the 2026 compounding nomination proposed a 0.1% cream or gel for wound healing and inflammatory skin conditions.[1] That strength was a proposal, not a tested dose. In a lab study on human skin, KPV did not pass through by simple contact at detectable levels. Tiny needle punctures and a mild electric current increased its delivery.[8] FDA similarly noted that KPV does not move through skin well, which could limit both its effects and its side effects.[1]
What about doses found online?
FDA found compounded or similar KPV products offered online as injections, oral products, creams and nasal sprays, alone or mixed with other peptides, for uses ranging from gut health to stroke.[1] The amounts on those labels and in online dosing charts do not come from any published human study. KPV is also one of four ingredients in the KLOW peptide blend, which has never been studied as a blend.
FDA also found that KPV is sold under one common name for different chemical forms (the free base and an acetate salt), and that the certificates of analysis it reviewed lacked tests for impurities, clumping and microbes.[1] So even the stated milligram amount in a product may not be reliable. If you are converting a vial’s milligrams into syringe units for any reason, our peptide calculator shows the arithmetic, but it cannot tell you what dose is appropriate.
Legal status in brief
- Not FDA-approved. No approved drug contains KPV.[1]
- Compounding: FDA had listed KPV among bulk substances that may pose significant safety risks; it now appears in the section of nominations that were withdrawn.[9]
- July 2026: FDA staff recommended against adding KPV to the list of substances pharmacies may compound with. Its advisory committee voted in favor anyway.[1][10] The vote is advice, and FDA had not issued a final decision as of our last review.
Questions to ask a clinician
- Is my gut or skin condition being treated with an approved therapy that has proven benefit?
- What would we watch for if I used an unapproved product, and when should I stop?
- Could this product interact with my other medicines or affect a planned test or surgery?
- Are there clinical trials for my condition that I could join instead?
There is no evidence-based KPV dose for a clinician to prescribe. For better-studied options, see our guides to the best peptides for gut health and peptides for inflammation. For what the research says about tumors, see KPV and cancer.
This is general information, not medical advice.
